Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587266 | 1.00 | AURKA (0.49) | AURKAAURKBLMNANAMPTTRPV1 | |
| SCHEMBL4589154 | 0.90 | AURKA (0.47) | AURKAAURKBLMNANAMPTBRD4 | |
| SCHEMBL4589158 | 0.90 | AURKA (0.47) | AURKAAURKBLMNANAMPTBRD4 | |
| SCHEMBL27742118 | 0.86 | BRD4 (0.46) | AURKAAURKBLMNANAMPTTRPV1 | |
| SCHEMBL4588279 | 0.83 | BRD4 (0.41) | AURKAAURKBLMNATRPV1BRD4 | |
| SCHEMBL4588284 | 0.83 | BRD4 (0.41) | AURKAAURKBLMNATRPV1BRD4 | |
| SCHEMBL4589624 | 0.81 | ALDH1A1 (0.51) | LMNABRD4KDM4EMAPTHPGD | |
| SCHEMBL4589620 | 0.81 | ALDH1A1 (0.51) | LMNABRD4KDM4EMAPTHPGD | |
| SCHEMBL3950696 | 0.79 | MEN1 (0.53) | AURKAAURKBLMNABRD4POLB | |
| SCHEMBL4588386 | 0.78 | BRD4 (0.56) | AURKAAURKBBRD4POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001846-A1 | INDOLE DERIVATIVES AS INHIBITORS OF THE SOLUBLE ADENYLATE CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-17 | — | — | EP | claimed |
| US-7449459-B2 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AG (DE) | 2008-11-11 | — | — | US | claimed |
| US-20070232605-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-04 | — | — | US | claimed |
| WO-2007107383-A1 | INDOLE DERIVATIVES AS INHIBITORS OF THE SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-27 | — | — | WO | claimed |
| EP-2001846-A1 | INDOLE DERIVATIVES AS INHIBITORS OF THE SOLUBLE ADENYLATE CYCLASE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-17 | — | — | EP | disclosed |
| US-7449459-B2 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AG (DE) | 2008-11-11 | — | — | US | disclosed |
| US-20070232605-A1 | Inhibitors of soluble adenylate cyclase | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007107383-A1 | INDOLE DERIVATIVES AS INHIBITORS OF THE SOLUBLE ADENYLATE CYCLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232605-A1 | Inhibitors of soluble adenylate cyclase | ADCY1, ADCY2, ADCYAP1R1 | AURKA 3236/4885AURKB 2727/4885LMNA 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.